Alere Receives FDA Clearance for Respiratory Syncytial Virus MDx

Aug 19, 2016

|

NEW YORK (GenomeWeb) – Alere announced today that it has received 510(k) clearance from the US Food and Drug Administration for a point-of-care isothermal nucleic acid amplification test that detects respiratory syncytial virus infection in children and adults from nasopharyngeal swab samples in 13 minutes or less.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Alere Receives FDA Clearance for Respiratory Syncytial Virus MDx

To read the full story....

Breaking News

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

New York City Opening Dedicated COVID-19 Testing Laboratory

Scipher Medicine Taps Ambry Genetics to Scale Up TNF Inhibitor Response Test

FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

AACC Calls on Congress to Fund Clinical Lab Training Programs

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

Bio-Techne, Qiagen Expand Partnership on Exosome Technology

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

Sponsorships